{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:40:29Z","timestamp":1783698029150,"version":"3.55.0"},"reference-count":37,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Mucopolysaccharidosis (MPS IVA) is caused by pathogenic variations in the GALNS gene, leading to the accumulation of glycosaminoglycans in tissues and causing progressive skeletal lesions. While conventional lentiviral vectors (LVs) provide long-term stable expression, they do not deliver therapeutic levels to bone and cartilage. We hypothesized that engineering the LV envelope with a collagen type II-targeting peptide (WYRGRL) increases the binding affinity of the LVs for bone and cartilage. These modified vectors carrying the CBh and COL2A1 promoters delivered the GALNS gene to MPS IVA newborn mice via intravenous (IV) or intraarticular (IA) administration. The peptide-modified LVs exhibited markedly increased uptake in the liver when administered IV, but lower enzyme activity than that of the conventional vector. The modified WYRGRL-LV-COL2A1 vector elevated GALNS activity in other tissues, suggesting systemic benefits. When administered IA, the modified vectors showed potential for local treatment due to the WYRGRL peptide-mediated uptake. Additionally, there was a reduction in keratan sulfate glycosaminoglycan levels in plasma and tissues, indicating that this peptide can be a suitable candidate for disease modification. These findings pave the way for further preclinical and clinical studies, offering new possibilities for the development of targeted therapies for skeletal diseases.<\/jats:p>","DOI":"10.3390\/cimb48010042","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T06:25:51Z","timestamp":1766989551000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Collagen Type II-Targeting Lentiviral Gene Therapy for Mucopolysaccharidosis IVA"],"prefix":"10.3390","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-8076","authenticated-orcid":false,"given":"Betul","family":"Celik","sequence":"first","affiliation":[{"name":"Nemours Children\u2019s Health, 1600 Rockland Rd., Wilmington, DE 19803, USA"},{"name":"Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7994-2032","authenticated-orcid":false,"given":"Sampurna","family":"Saikia","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Health, 1600 Rockland Rd., Wilmington, DE 19803, USA"},{"name":"Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaukat","family":"Khan","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Health, 1600 Rockland Rd., Wilmington, DE 19803, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-462X","authenticated-orcid":false,"given":"Krishna Sai","family":"Musini","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Health, 1600 Rockland Rd., Wilmington, DE 19803, USA"},{"name":"Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-2160","authenticated-orcid":false,"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Health, 1600 Rockland Rd., Wilmington, DE 19803, USA"},{"name":"Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA"},{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan"},{"name":"Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","article-title":"International Morquio A Registry: Clinical manifestation and natural course of Morquio A disease","volume":"30","author":"Tomatsu","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s10038-019-0604-6","article-title":"Effect of enzyme replacement therapy on the growth of patients with Morquio A","volume":"64","author":"Doherty","year":"2019","journal-title":"J. Hum. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1002\/ajmg.a.62469","article-title":"The youngest pair of siblings with Mucopolysaccharidosis type IVA to receive enzyme replacement therapy to date: A case report","volume":"185","author":"Frigeni","year":"2021","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_4","first-page":"42","article-title":"30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case","volume":"9","author":"Cao","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sawamoto, K., Gonz\u00e1lez, J.V.\u00c1., Piechnik, M., Otero, F.J., Couce, M.L., Suzuki, Y., and Tomatsu, S. (2020). Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041517"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/21678707.2015.1086640","article-title":"Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): Effect and limitations","volume":"3","author":"Tomatsu","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/hmg\/ddm353","article-title":"Enzyme replacement therapy in a murine model of Morquio A syndrome","volume":"17","author":"Tomatsu","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ymgme.2014.05.013","article-title":"Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: Early treatment rescues bone lesions?","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.omtm.2020.05.015","article-title":"Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model","volume":"18","author":"Sawamoto","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s44321-024-00072-8","article-title":"GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice","volume":"16","author":"Milani","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eaav7325","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103802","DOI":"10.1016\/j.cellimm.2018.04.012","article-title":"Modulation of immune responses in lentiviral vector-mediated gene transfer","volume":"342","author":"Annoni","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41413-019-0046-y","article-title":"Collagen type II suppresses articular chondrocyte hypertrophy and osteoarthritis progression by promoting integrin \u03b21\u2212SMAD1 interaction","volume":"7","author":"Lian","year":"2019","journal-title":"Bone Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"E1044","DOI":"10.1152\/ajpendo.00170.2010","article-title":"Intraspecies disparity in growth rate is associated with differences in expression of local growth plate regulators","volume":"299","author":"Tryfonidou","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/labinvest.2015.142","article-title":"Wnt signaling in cartilage development and diseases: Lessons from animal studies","volume":"96","author":"Usami","year":"2016","journal-title":"Lab. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/cge.13680","article-title":"Integrated analysis of COL2A1 variant data and classification of type II collagenopathies","volume":"97","author":"Zhang","year":"2019","journal-title":"Clin. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/jor.20200","article-title":"Limitations of using aggrecan and type X collagen as markers of chondrogenesis in mesenchymal stem cell differentiation","volume":"24","author":"Mwale","year":"2006","journal-title":"J. Orthop. Res."},{"key":"ref_18","unstructured":"Adolphe, M. (1992). Biological Regulation of the Chondrocytes, CRC Press."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e37786","DOI":"10.1002\/jbm.a.37786","article-title":"Collagen binding and mimetic peptide-functionalized self-assembled peptide hydrogel enhance chondrogenic differentiation of human mesenchymal stem cells","volume":"113","author":"Pulat","year":"2025","journal-title":"J. Biomed. Mater. Res. A"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1039\/D2TB02157A","article-title":"Early diagnosis of heterotopic ossification with a NIR fluorescent probe by targeting type II collagen","volume":"11","author":"Wang","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1039\/C8BM01440J","article-title":"A NIR-II fluorescent probe for articular cartilage degeneration imaging and osteoarthritis detection","volume":"7","author":"Yi","year":"2019","journal-title":"Biomater. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2101715","DOI":"10.1002\/adhm.202101715","article-title":"Harnessing Bifunctional Ferritin with Kartogenin Loading for Mesenchymal Stem Cell Capture and Enhancing Chondrogenesis in Cartilage Regeneration","volume":"11","author":"Ren","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12951-023-02050-7","article-title":"Injectable photocrosslinking spherical hydrogel-encapsulated targeting peptide-modified engineered exosomes for osteoarthritis therapy","volume":"21","author":"Wan","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2018.12.025","article-title":"Cartilage-targeting dexamethasone prodrugs increase the efficacy of dexamethasone","volume":"295","author":"Formica","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_25","first-page":"169","article-title":"Dual-engineered cartilage-targeting extracellular vesicles derived from mesenchymal stem cells enhance osteoarthritis treatment via miR-223\/NLRP3\/pyroptosis axis: Toward a precision therapy","volume":"30","author":"Liu","year":"2023","journal-title":"Bioact. Mater."},{"key":"ref_26","first-page":"2372","article-title":"Cartilage-targeting peptide-modified dual-drug delivery nanoplatform with NIR laser response for osteoarthritis therapy","volume":"6","author":"Xue","year":"2021","journal-title":"Bioact. Mater."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmat2116","article-title":"Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage","volume":"7","author":"Rothenfluh","year":"2008","journal-title":"Nat. Mater."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/bph.14516","article-title":"Targeting the extracellular matrix for delivery of bioactive molecules to sites of arthritis","volume":"176","author":"Schultz","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Berillo, D., Yeskendir, A., Zharkinbekov, Z., Raziyeva, K., and Saparov, A. (2021). Peptide-Based Drug Delivery Systems. Medicina, 57.","DOI":"10.3390\/medicina57111209"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Celik, B., Rintz, E., Khan, S., Leal, A.F., Nidhi, F., and Tomatsu, S. (Mol. Ther. Methods Clin. Dev., 2025). In Vivo Direct Lentiviral Gene Therapy Improves Disease Pathology in a Mucopolysaccharidosis IVA Murine Model, Mol. Ther. Methods Clin. Dev., in press.","DOI":"10.1016\/j.omtm.2025.101514"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2016.12.010","article-title":"Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses","volume":"120","author":"Kubaski","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_32","first-page":"1","article-title":"Di-sulfated Keratan Sulfate as a Novel Biomarker for Mucopolysaccharidosis II, IVA, and IVB","volume":"21","author":"Shimada","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/hum.2024.094","article-title":"Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model","volume":"35","author":"Celik","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1359\/jbmr.071115","article-title":"Overexpression of Smurf2 Stimulates Endochondral Ossification Through Upregulation of \u03b2-Catenin","volume":"23","author":"Wu","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103737","DOI":"10.1016\/j.cellimm.2017.12.011","article-title":"Immunomodulatory, liver depot gene therapy for Pompe disease","volume":"342","author":"Bond","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"277ra28","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver-directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-3-69","article-title":"The effects of N-terminal insertion into VSV-G of an scFv peptide","volume":"3","author":"Dreja","year":"2006","journal-title":"Virol. J."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/1\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T05:18:26Z","timestamp":1767071906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/1\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cimb48010042"],"URL":"https:\/\/doi.org\/10.3390\/cimb48010042","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]}}}